Dimerix Quarterly Activities Report and Appendix 4C
Filed with ASX · · 11 pages · English
Story so far
Earlier from Dimerix
- New Data Supports Biological Rationale for DMX-200 in FSGS
- 2026 AGM Notice of Meeting, Letter of Access and Proxy Form
- Dimerix Announces Board Chair Transition
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
- Dimerix at Canaccord Drug & Device and Ignite Conferences
Later from Dimerix
All Dimerix news releasesFollow Dimerix into a list and get an email when it puts out news.
Follow Dimerix